Your patient's initial cognitive complaint or observed impairment may be your trigger to detect, assess, and diagnose early-stage AD. A key part of the process can be biomarker confirmation to support the diagnosis.1-4
According to International Working Group (IWG) recommendations, a diagnosis of AD requires a clinical evaluation and confirmation of AD pathology. The diagnostic value of AD as the cause of MCI provides the clinician an opportunity to initiate patient care.7
There are a wide variety of biomarkers available for neuropathological diagnosis of AD. For instance, positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) tests can determine whether amyloid beta (Aβ) and tau pathology are present in the brain, biomarkers that are currently considered valid proxies for neuropathologic changes of AD.8
Many other biomarkers that are commonly used in research are non-specific indicators of neuronal damage. And while magnetic resonance imaging (MRI) is widely available and recommended as part of the diagnostic criteria, especially to rule out other possible causes, it lacks molecular specificity and cannot confirm AD pathology.9